BELVIQ¿ (Lorcaserin HCl) Tablets, 10 mg, 60-count bottle, Rx only, Manufactured by: Arena Pharmaceuticals, GmbH, Zofingen, Switzerland, Distributed by: Elsai Inc., Woodcliff, NJ 07677 NDC 62856-52960.

Recall Insight

This FDA Drug action (record #D-0302-2015) was formally reported on December 24, 2014, with the manufacturer initiating the action on December 5, 2014. It is classified under Low severity (Class III), with a current status of Terminated. Eisai Inc is listed as the recalling firm, operating out of Research Triangle Park, NC. Federal records indicate 121,680 bottles units are affected, a scale large enough to require multi-state distribution tracking.

The documented reason for this recall is: Labeling:Missing Label: Bottles may not have a product label, or have a label with missing or illegible lot number and/or expiry date. Distribution data in the federal record shows the product reached: Nationwide.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

To put this record in context, PlainRecalls indexes 83,949 recalls across the FDA, CPSC, NHTSA and USDA FSIS going back to 1995. Within the same product category, the database holds 6 closely related recalls, of which 5 were also issued by FDA Drug. That clustering is a signal — repeated actions in a narrow category often indicate a systemic quality-control issue, a supplier-wide contamination, or a design defect that has propagated across product lines. This recall is roughly 12 years old; older recalls can remain relevant because many units enter resale, rental, and secondary-market channels where the original warning never reaches the end user. Always cross-check the recall number against the official agency page before relying on any summary.